


## PHARMACEUTICAL 2017

## Sibannac Inc. Rank 214 of 313





## PHARMACEUTICAL 2017

## Sibannac Inc. Rank 214 of 313

The relative strengths and weaknesses of Sibannac Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sibannac Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 351% points. The greatest weakness of Sibannac Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 370% points.

The company's Economic Capital Ratio, given in the ranking table, is -372%, being 44% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	73
Cost of Goods Sold	453
Intangible Assets	0
Liabilities, Current	366
Liabilities, Non-Current	250
Other Assets	250
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-152
Property and Equipment	0
Research and Development	0
Revenues	524
Selling, General and Administrative Expense	270

Output Variable	Value in 1000 USD
Assets	323
Liabilities	616
Expenses	723
Stockholders Equity	-293
Net Income	-351
Comprehensive Net Income	-351
Economic Capital Ratio	-372%